A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : BAS / bile acid sequestrants

[Related PubMed/MEDLINE]
Total Number of Papers: 39
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   BAS  (>> Co-occurring Abbreviation)
Long Form:   bile acid sequestrants
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Bile Acid Sequestration Reverses Liver Injury and Prevents Progression of NASH in Western Diet-Fed Mice. NAFLD, NASH
2018 Polymeric bile acid sequestrants: Review of design, invitro binding activities, and hypocholesterolemic effects. BA
2017 Incidence and predictive factors for positive 75SeHCAT test: improving the diagnosis of bile acid diarrhoea. BAD
2017 The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: A systematic review and meta-analysis of randomized controlled trials. FBG, TC, WMD
2016 A Multicenter Prospective Study to Investigate the Diagnostic Accuracy of the SeHCAT Test in Measuring Bile Acid Malabsorption: Research Protocol. BAM, FGF19
2016 Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. CDCA, GLP-1
2016 Long-term outcomes in patients diagnosed with bile-acid diarrhoea. BAD, SeHCAT
2016 Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors. CVRFs, FXR, TGR5
2016 Multicentre prospective survey of SeHCAT provision and practice in the UK. BAM
10  2015 Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis. CAD, CI, LDL-C
11  2015 In vitro and in vivo evaluation of novel cross-linked saccharide based polymers as bile acid sequestrants. beta-CD, Chol, DVS
12  2015 Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy. BAM, NICE, SeHCAT
13  2014 Colesevelam and colestipol: novel medication resins in the gastrointestinal tract. ---
14  2013 A review of the efficacy and safety of oral antidiabetic drugs. AGIs, GI, SU, TZD
15  2013 Bile acid sequestration normalizes plasma cholesterol and reduces atherosclerosis in hypercholesterolemic mice. No additional effect of physical activity. BAS RUN, RUN
16  2013 Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond. ---
17  2012 Bile acid sequestrants: more than simple resins. ---
18  2012 Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. MRI, MRS, NASH, PDFF
19  2012 Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes. LDL-C
20  2011 Bile acid sequestration reduces plasma glucose levels in db/db mice by increasing its metabolic clearance rate. ---
21  2011 Clinical efficacy of colesevelam in type 2 diabetes mellitus. FDA, HbA1c, LDL-C, non-HDL-C, T2DM
22  2011 Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes. ---
23  2010 Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. FXR, GLP-1, HbA1c, LXR, PYY, ZDF
24  2010 Combination of fenofibrate with non-statin drug regimens. ---
25  2010 Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus. HCl, LDL-C, T2DM
26  2010 Role of bile acid sequestrants in the treatment of type 2 diabetes. LDL
27  2010 The Bile Acid Sequestrant Acceptability scale validation study. BASA
28  2009 Lipid-lowering drugs acting at the level of the gastrointestinal tract. CVD, GI, LDL-C, TG
29  2008 Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. LDL-C
30  2008 Recognition and management of dyslipidemia in children and adolescents. CVD
31  2007 Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. CHD, LDL
32  2007 Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. CHD, T2DM
33  2007 Safety considerations with gastrointestinally active lipid-lowering drugs. CAIs
34  2007 The 'forgotten' bile acid sequestrants: is now a good time to remember? CHD
35  2006 Bile acid salt binding with colesevelam HCl is not affected by suspension in common beverages. GC, GCDC, HCl, HPLC, SIF, TDC
36  2006 Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. CAD, HCl, LDL-C
37  2000 Bile acid malabsorption in persistent diarrhoea. BAM
38  1998 Studies of cholesterol and bile acid metabolism, and early atherogenesis in hamsters fed GT16-239, a novel bile acid sequestrant (BAS). HDL-C, TC
39  1994 Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. ---